Literature DB >> 21789793

Addendum to "Strain-to-strain difference of V protein of measles virus affects MDA5-mediated IFN-β-inducing potential" [Mol. Immunol. 48(4) (2011) 497-504].

Tsukasa Seya1.   

Abstract

Measles virus (MV) V protein blocks type I IFN signaling in MV-infected cells. Previous studies suggested that some MV strains could release the V protein-mediated type I IFN suppression in affected cells by two distinct modes: V protein mutation and production of DI RNA. These two modes of type I interferon regulation involves the IPS-1 (MAVS, Cardif, VISA) pathway (Takaki et al., 2011. Mol. Immunol. 48(4), 497–504). We add the comment to this previous issue that the release of the V protein-mediated suppression of type I IFN occurs only by a laboratory-adapted strain of Edmonston.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21789793     DOI: 10.1016/j.molimm.2011.04.007

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  4 in total

Review 1.  Measles Vaccine.

Authors:  Diane E Griffin
Journal:  Viral Immunol       Date:  2017-12-19       Impact factor: 2.257

2.  Limited in vivo production of type I or type III interferon after infection of macaques with vaccine or wild-type strains of measles virus.

Authors:  Rupak Shivakoti; Debra Hauer; Robert J Adams; Wen-Hsuan W Lin; William Paul Duprex; Rik L de Swart; Diane E Griffin
Journal:  J Interferon Cytokine Res       Date:  2014-12-17       Impact factor: 2.607

3.  Induction of dendritic cell production of type I and type III interferons by wild-type and vaccine strains of measles virus: role of defective interfering RNAs.

Authors:  Rupak Shivakoti; Martina Siwek; Debra Hauer; Kimberly L W Schultz; Diane E Griffin
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

4.  Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis.

Authors:  Susanne Berchtold; Johanna Lampe; Timo Weiland; Irina Smirnow; Sabine Schleicher; Rupert Handgretinger; Hans-Georg Kopp; Jeanette Reiser; Frank Stubenrauch; Nora Mayer; Nisar P Malek; Michael Bitzer; Ulrich M Lauer
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.